Abstract
Despite therapeutic advancements, disease-free survival and overall survival of patients with locally advanced rectal cancer have not improved in most trials as a result of distant metastases. For treatment decision-making, both long-term oncologic outcomes and impact on quality-of-life indices should be considered (for example, bowel function). Total neoadjuvant therapy (TNT), comprised of chemotherapy and radiotherapy or chemoradiotherapy, is now a standard treatment approach in patients with features of high-risk disease to prevent local recurrence and distant metastases. In selected patients who have a clinical complete response, subsequent surgery might be avoided through non-operative management, but patients who do not respond to TNT have a poor prognosis. Refined molecular characterization might help to predict which patients would benefit from TNT and non-operative management. Specifically, integrated analysis of spatiotemporal multi-omics using artificial intelligence and machine learning is promising. Three prospective trials of TNT and non-operative management in Japan, the USA and Germany are collaborating to better understand drivers of response to TNT. Here, we address the future direction for TNT.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
Abualkhair, W. H. et al. Geographic and intra-racial disparities in early-onset colorectal cancer in the SEER 18 registries of the United States. Cancer Med. 9, 9150–9159 (2020).
Spaander, M. C. W. et al. Young-onset colorectal cancer. Nat. Rev. Dis. Primers 9, 21 (2023).
Meester, R. G. S., Mannalithara, A., Lansdorp-Vogelaar, I. & Ladabaum, U. Trends in incidence and stage at diagnosis of colorectal cancer in adults aged 40 through 49 years, 1975-2015. JAMA 321, 1933–1934 (2019).
Dozois, E. J. et al. Young-onset colorectal cancer in patients with no known genetic predisposition: can we increase early recognition and improve outcome. Medicine 87, 259–263 (2008).
Adam, I. J. et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 344, 707–711 (1994).
Heald, R. J., Husband, E. M. & Ryall, R. D. The mesorectum in rectal cancer surgery — the clue to pelvic recurrence? Br. J. Surg. 69, 613–616 (1982).
Heald, R. J. & Ryall, R. D. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1, 1479–1482 (1986).
Enker, W. E. Potency, cure, and local control in the operative treatment of rectal cancer. Arch. Surg. 127, 1396–1401 (1992).
Heald, R. J. & Karanjia, N. D. Results of radical surgery for rectal cancer. World J. Surg. 16, 848–857 (1992).
van der Pas, M. H. et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol. 14, 210–218 (2013).
Jones, K., Qassem, M. G., Sains, P., Baig, M. K. & Sajid, M. S. Robotic total meso-rectal excision for rectal cancer: a systematic review following the publication of the ROLARR trial. World J. Gastrointest. Oncol. 10, 449–464 (2018).
Glynne-Jones, R. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28, iv22–iv40 (2017).
NCCN Clinical Practice Guidelines in Oncology. Rectal Cancer Version 5, 2023. NCCN https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf (2023).
Lambregts, D. M. J. et al. Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus. Eur. Radiol. 32, 4991–5003 (2022).
Keller, D. S., Berho, M., Perez, R. O., Wexner, S. D. & Chand, M. The multidisciplinary management of rectal cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 414–429 (2020).
Fujita, S. et al. Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (JCOG0212): a multicenter, randomized controlled, noninferiority trial. Ann. Surg. 266, 201–207 (2017).
Tsukamoto, S. et al. Long-term follow-up of the randomized trial of mesorectal excision with or without lateral lymph node dissection in rectal cancer (JCOG0212). Br. J. Surg. 107, 586–594 (2020).
Aschele, C. et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J. Clin. Oncol. 29, 2773–2780 (2011).
Gérard, J. P. et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J. Clin. Oncol. 30, 4558–4565 (2012).
Rödel, C. et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 16, 979–989 (2015).
Allegra, C. J. et al. Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J. Natl Cancer Inst. 107, djv248 (2015).
Bosset, J. F. et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 15, 184–190 (2014).
Sainato, A. et al. No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother. Oncol. 113, 223–229 (2014).
Sharma, R. A comparative examination of colorectal cancer burden in European Union, 1990-2019: estimates from Global Burden of Disease 2019 Study. Int. J. Clin. Oncol. 27, 1309–1320 (2022).
Sebag-Montefiore, D. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373, 811–820 (2009).
Peeters, K. C. et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann. Surg. 246, 693–701 (2007).
van Gijn, W. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 12, 575–582 (2011).
Rödel, C. et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 13, 679–687 (2012).
Carvalho, C. & Glynne-Jones, R. Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. Lancet Oncol. 18, e354–e363 (2017).
Bahadoer, R. R. et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 29–42 (2021).
Conroy, T. et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 22, 702–715 (2021).
Jin, J. et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J. Clin. Oncol. 40, 1681–1692 (2022).
Dijkstra, E. A. et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery — a five-year follow-up of the RAPIDO trial. Ann. Surg. 278, e766–e772 (2023).
Etienne, P.-L. et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial. J. Clin. Oncol. 41, LBA3504 (2023).
Shi, D. D. & Mamon, H. J. Playing with dynamite? A cautious assessment of TNT. J. Clin. Oncol. 39, 103–106 (2021).
Glynne-Jones, R. & Harrison, M. Should the RAPIDO schedule represent standard of care in locally advanced rectal cancer? Ann. Oncol. 33, 745–746 (2022).
Glynne-Jones, R. & Hollingshead, J. TNT and local recurrence in the RAPIDO trial — untangling the puzzle. Nat. Rev. Clin. Oncol. 20, 357–358 (2023).
Emons, G. et al. Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy. Br. J. Cancer 127, 766–775 (2022).
Schrag, D. et al. Preoperative treatment of locally advanced rectal cancer. N. Engl. J. Med. 389, 322–334 (2023).
Fokas, E. et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J. Clin. Oncol. 37, 3212–3222 (2019).
Fokas, E. et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol. 8, e215445 (2022).
Garcia-Aguilar, J. et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J. Clin. Oncol. 40, 2546–2556 (2022).
Verheij, F. S. et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J. Clin. Oncol. 42, 500–506 (2024).
Sauer, R. et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J. Clin. Oncol. 30, 1926–1933 (2012).
Folkesson, J. et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J. Clin. Oncol. 23, 5644–5650 (2005).
Roh, M. S. et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J. Clin. Oncol. 27, 5124–5130 (2009).
Ngan, S. Y. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. J. Clin. Oncol. 30, 3827–3833 (2012).
Bujko, K. et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br. J. Surg. 93, 1215–1223 (2006).
McLachlan, S. A. et al. The impact on health-related quality of life in the first 12 months: a randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). Eur. J. Cancer 55, 15–26 (2016).
Pietrzak, L. et al. Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomised trial. Radiother. Oncol. 84, 217–225 (2007).
Ciseł, B. et al. Long-course preoperative chemoradiation versus 5×5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann. Oncol. 30, 1298–1303 (2019).
Liao, C. K. et al. Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis. Curr. Oncol. 29, 3708–3727 (2022).
Romesser, P. B. et al. Organ preservation and total neoadjuvant therapy for rectal cancer: investigating long-course chemoradiation versus short-course radiation therapy. J. Clin. Oncol. 41, (Suppl. 4), 10 (2023).
Watanabe, J. et al. Phase III trial of short-course radiotherapy followed by CAPOXIRI versus CAPOX in locally advanced rectal cancer: the ENSEMBLE trial. ESMO Gastrointest. Oncol. 1, 9–14 (2023).
Erlandsson, J. et al. Tumour regression after radiotherapy for rectal cancer — results from the randomised Stockholm III trial. Radiother. Oncol. 135, 178–186 (2019).
Benson, A. B. et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 16, 874–901 (2018).
Wo, J. Y. et al. Radiation therapy for rectal cancer: executive summary of an ASTRO clinical practice guideline. Pract. Radiat. Oncol. 11, 13–25 (2021).
Garcia-Aguilar, J. et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 16, 957–966 (2015).
Sauer, R. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351, 1731–1740 (2004).
Bosset, J. F. et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med. 355, 1114–1123 (2006).
Gérard, J. P. et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J. Clin. Oncol. 24, 4620–4625 (2006).
Gérard, J. P. et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J. Clin. Oncol. 28, 1638–1644 (2010).
Valentini, V. et al. The INTERACT trial: long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer. Radiother. Oncol. 134, 110–118 (2019).
Gambacorta, M. A. et al. Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials. Radiother. Oncol. 154, 154–160 (2021).
Deidda, S. et al. Association of delayed surgery with oncologic long-term outcomes in patients with locally advanced rectal cancer not responding to preoperative chemoradiation. JAMA Surg. 156, 1141–1149 (2021).
Luo, D., Yang, Y., Zhang, R., Li, Q. & Li, X. Effect of interval between neoadjuvant chemoradiotherapy and surgery on oncological outcomes in poor responders with locally advanced rectal cancer: a retrospective cohort study. Int. J. Surg. 109, 1993–2000 (2023).
Habr-Gama, A. et al. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: the impact of radiation therapy dose-escalation and consolidation chemotherapy. Ann. Surg. 269, 102–107 (2019).
Smith, J. J. et al. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 15, 767 (2015).
Lynn, P. B., Strombom, P. & Garcia-Aguilar, J. Organ-preserving strategies for the management of near-complete responses in rectal cancer after neoadjuvant chemoradiation. Clin. Colon Rectal Surg. 30, 395–403 (2017).
Maas, M. et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann. Surg. Oncol. 22, 3873–3880 (2015).
Fokas, E. et al. International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. Nat. Rev. Clin. Oncol. 18, 805–816 (2021).
Garcia-Aguilar, J. et al. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. J. Clin. Oncol. 38, 4008–4008 (2020).
Maas, M. et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 11, 835–844 (2010).
Ortholan, C., Romestaing, P., Chapet, O. & Gerard, J. P. Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96-02 randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 83, e165–e171 (2012).
Valentini, V. et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J. Clin. Oncol. 29, 3163–3172 (2011).
Zorcolo, L. et al. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann. Surg. Oncol. 19, 2822–2832 (2012).
Capirci, C. et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int. J. Radiat. Oncol. Biol. Phys. 72, 99–107 (2008).
Rödel, C. et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J. Clin. Oncol. 23, 8688–8696 (2005).
Smith, J. J. et al. Assessment of a watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 5, e185896 (2019).
Fernandez, L. M. et al. The risk of distant metastases in patients with clinical complete response managed by watch and wait after neoadjuvant therapy for rectal cancer: the influence of local regrowth in the international watch and wait database. Dis. Colon. Rectum 66, 41–49 (2023).
Custers, P. A. et al. Long-term quality of life and functional outcome of patients with rectal cancer following a watch-and-wait approach. JAMA Surg. 158, e230146 (2023).
Quezada-Diaz, F. F. et al. Patient-reported bowel function in patients with rectal cancer managed by a watch-and-wait strategy after neoadjuvant therapy: a case-control study. Dis. Colon Rectum 20, 897–902 (2020).
Battersby, N. J. et al. Predicting the risk of bowel-related quality-of-life impairment after restorative resection for rectal cancer: a multicenter cross-sectional study. Dis. Colon. Rectum 59, 270–280 (2016).
Papke, D. J. Jr. et al. Prevalence of mismatch-repair deficiency in rectal adenocarcinomas. N. Engl. J. Med. 387, 1714–1716 (2022).
Alatise, O. I. et al. Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nat. Commun. 12, 6821 (2021).
Cercek, A. et al. Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin. Cancer Res. 26, 3271–3279 (2020).
Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363–2376 (2022).
Kagawa, H. et al. Consensus molecular subtyping improves the clinical usefulness of canonical tumor markers for colorectal cancer. Biomed. Res. 43, 201–209 (2022).
Loftus, T. J. et al. Artificial intelligence and surgical decision-making. JAMA Surg. 155, 148–158 (2020).
Foersch, S. et al. Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer. Nat. Med. 29, 430–439 (2023).
Itahashi, K. et al. Evaluating clinical genome sequence analysis by watson for genomics. Front. Med. 5, 305 (2018).
Nakamura, Y. et al. SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: path to the realization of biomarker-guided precision oncology in advanced solid tumors. Cancer Sci. 112, 4425–4432 (2021).
Bando, H., Ohtsu, A. & Yoshino, T. Therapeutic landscape and future direction of metastatic colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 20, 306–322 (2023).
Gillies, R. J., Kinahan, P. E. & Hricak, H. Radiomics: images are more than pictures, they are data. Radiology 278, 563–577 (2016).
Wang, J. et al. Development and validation of an MRI-based radiomic nomogram to distinguish between good and poor responders in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy. Abdom. Radiol. 46, 1805–1815 (2021).
Liu, Z. et al. Radiomics analysis for evaluation of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Clin. Cancer Res. 23, 7253–7262 (2017).
Li, Z. et al. Radiomics analysis of multi-sequence MR images for predicting microsatellite instability status preoperatively in rectal cancer. Front. Oncol. 11, 697497 (2021).
Di Costanzo, G. et al. Artificial intelligence and radiomics in magnetic resonance imaging of rectal cancer: a review. Explor. Target. Antitumor Ther. 4, 406–421 (2023).
Nicolas, A. M. et al. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. Cancer Cell 40, 168–184.e13 (2022).
Kagawa, Y. et al. Short‐term outcomes of a prospective multicenter phase II trial of total neoadjuvant therapy for locally advanced rectal cancer in Japan (ENSEMBLE‐1). Ann. Gastroenterol. Surg. 7, 968–976 (2023).
Reel, P. S., Reel, S., Pearson, E., Trucco, E. & Jefferson, E. Using machine learning approaches for multi-omics data analysis: a review. Biotechnol. Adv. 49, 107739 (2021).
Ikemura, S. et al. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc. Natl Acad. Sci. USA 116, 10025–10030 (2019).
Luchini, C., Pea, A. & Scarpa, A. Artificial intelligence in oncology: current applications and future perspectives. Br. J. Cancer 126, 4–9 (2022).
Akilandeswari, A. et al. Automatic detection and segmentation of colorectal cancer with deep residual convolutional neural network. Evid. Based Complement. Altern. Med. 2022, 3415603 (2022).
Mansur, A., Saleem, Z., Elhakim, T. & Daye, D. Role of artificial intelligence in risk prediction, prognostication, and therapy response assessment in colorectal cancer: current state and future directions. Front. Oncol. 13, 1065402 (2023).
Boggi, U. Precision surgery. Updates Surg. 75, 3–5 (2023).
Mazaki, J. et al. A novel predictive model for anastomotic leakage in colorectal cancer using auto-artificial intelligence. Anticancer Res. 41, 5821–5825 (2021).
Wang, A. et al. Machine learning of histomorphological features predict response to neoadjuvant therapy in locally advanced rectal cancer. J. Gastrointest. Surg. 27, 162–165 (2023).
Shin, J. et al. MRI radiomics model predicts pathologic complete response of rectal cancer following chemoradiotherapy. Radiology 303, 351–358 (2022).
Zhang, L., Zhao, Y., Che, T., Li, S. & Wang, X. Graph neural networks for image-guided disease diagnosis: a review. iRADIOLOGY 1, 151–166 (2023).
Losurdo, P. et al. microRNAs combined to radiomic features as a predictor of complete clinical response after neoadjuvant radio-chemotherapy for locally advanced rectal cancer: a preliminary study. Surg. Endosc. 37, 3676–3683 (2023).
Okagawa, Y., Abe, S., Yamada, M., Oda, I. & Saito, Y. Artificial intelligence in endoscopy. Dig. Dis. Sci. 67, 1553–1572 (2022).
Samadi, P. et al. An integrative transcriptome analysis reveals potential predictive, prognostic biomarkers and therapeutic targets in colorectal cancer. BMC Cancer 22, 835 (2022).
Chatila, W. K. et al. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nat. Med. 28, 1646–1655 (2022).
Acknowledgements
ENSEMBLE was funded by the Japan Agency for Medical Research and Department (AMED, no. 21ck0106687h0001, no. 21ck0106696h0001 and no. 22ck0106870h0001). The Janus Rectal Cancer Trial (NCT05610163) is supported by U10CA180821. P.B.R. is supported by an NIH/NCI grant (K08 CA255574). J.J.S. is supported by an NIH/NCI grant (R37 CA248289).
Author information
Authors and Affiliations
Contributions
Y.K., J.J.S., E.F., C.R. and T.Y. researched data for the article. Y.K., J.J.S., E.F., J.W., A.C., H.B., P.B.R., N.H., T.K., C.R. and T.Y. contributed substantially to the discussion of content. Y.K., J.J.S., E.F. and T.Y. wrote the article. All authors reviewed and/or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
Y.K. received honoraria for lectures from Johnson & Johnson, Intuitive Surgical Medtronic, Eli Lilly, Chugai, Ono, MSD, Merck Biopharma and Takeda, and received research funding from Ono and Takeda. J.J.S. received travel support for fellow education from Intuitive Surgical (2015). He served as a clinical adviser for Guardant Health (2019) and for Foundation Medicine (2022), and served as a consultant and speaker for Johnson & Johnson (2022). He also serves as a clinical advisor and consultant for GSK (2023). J.W. received honoraria for lectures from Johnson & Johnson, Medtronic, Eli Lilly and Takeda, and received research funding from Medtronic, Terumo, Amco and Stryker Japan outside the submitted work. A.C. is on the advisory board for Bayer, Merck, GSK, Seagen, Roche, Pfizer and Illumina, has received research funding from Seagen and GSK, and has equity in Haystack Oncology. H.B. reports research funding from Ono Pharmaceutical and honoraria from Taiho Pharmaceutical and Eli Lilly, Japan. Q.S. reports a consulting/advisory role from Yiviva Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Hoosier Cancer Research Network, Kronos Bio and Mirati Therapeutics Inc., a personal honorarium/speaker role from Chugai Pharmaceutical Co., Ltd. and research funds to their institution from Celgene/BMS, Roche/Genentech, Janssen and Novartis. J.G.-A. has relevant disclosures as noted: Johnson & Johnson (honorarium), Medtronic (honorarium) and Intuitive Surgical (honorarium, stock). P.B.R. is a consultant for Natera. N.H. received a lecture fee from Bayer (2022), served as a consultant for Guerbet (2023) and received travel support for a radiology meeting from Guerbet (2023). H.S. has received research funding from Amgen, AstraZeneca, BioMed Valley Discoveries, Bristol Myers Squibb, Exelixis, Pfizer, Rgenix and F Hoffman LaRoche. W.H. is a consultant for Aktis oncology outside of the submitted work, Medical College of Wisconsin holds a provisional patent, inventors William A. Hall and Eric Paulson, number 63/483,252, status is provisional, no aspect of the manuscript is covered in the patent application, the patent is outside of the submitted work. W.H. serves on the clinical steering committee for the Atlantic MR Linac consortium sponsored by Elekta AB and is the pancreatic site lead for this research consortium. Elekta AB provides institutional research and travel support to the Medical College of Wisconsin Department of Radiation Oncology. T.K. reports honoraria from Chugai Pharmaceutical, Takeda Pharmaceutical Company Limited, ONO Pharmaceutical Co., Eli Lilly and Company and Yakult Honsha Company and research funding from Taiho Pharmaceutical. A.D. received consulting fees from HUTCHMED, Takeda, Illumina, Personalis, AAA/Novartis, Ipsen and Sirtex, and research funding (institutional) from HUTCHMED, Xencor, Guardant Health, Eisai, Natera, Enterome and Taiho. T.Y. reports research funding from Taiho, Ono, Chugai, Amgen, MSD, Daiichi-Sankyo, Eisai, FALCO biosystems, Genomedia, Molecular Health, Nippon Boehringer Ingelheim, Pfizer, Roche Diagnostics, Sysmex and Sanofi; honoraria from Bayer, Chugai, Merck Biopharma, MSD, Ono and Takeda; consulting role from Sumitomo Corp.; and consulting fee from Sumitomo Corp. The other authors declare no competing interests.
Peer review
Peer review information
Nature Reviews Gastroenterology & Hepatology thanks S. Pucciarelli, who co-reviewed with G. Spolverato; A. Heriot; A. Grothey; and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kagawa, Y., Smith, J.J., Fokas, E. et al. Future direction of total neoadjuvant therapy for locally advanced rectal cancer. Nat Rev Gastroenterol Hepatol (2024). https://doi.org/10.1038/s41575-024-00900-9
Accepted:
Published:
DOI: https://doi.org/10.1038/s41575-024-00900-9